. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Acta Neuropathol. 2013 Jun 29;126(5):10.1007/s00401-013-1151-4. doi: 10.1007/s00401-013-1151-4

Table 3.

Mixed-effects model adjusting for baseline biomarkers: effects of baseline diagnostic group and follow-up time

	Diagnosis MCI		Diagnosis AD		APOE ε4		Baseline Aβ_1–42		Baseline p-Tau₁₈₁
	Baseline	Change	Baseline	Change	Baseline	Change	Baseline	Change	Baseline	Change
Aβ_1–42	t = −2.8; p = 0.006	t = 0.6.; p = 0.54	t = −2.1; p = 0.03	t = 0.6; p = 0.54	t = −4.9; p < 0.0001	t = 1.0; p = 0.31	–	–	t = −4.5; p < 0.0001	t = 0.6; p = 0.52
T-Tau	t = 2.0; p = 0.046	t = −0.5; p = 0.62	t = 2.6; p = 0.009	t = −2.2; p = 0.03	t = 1.7; p = 0.08	t = 0.48; p = 0.63	t = −2.3; p = 0.02	t = −0.78; p = 0.44	–	–
P-Tau₁₈₁	t = 1.2; p = 0.25	t = 0.4; p = 0.67	t = 1.1; p = 0.25	t = 0.1; p = 0.90	t = 1.9; p = 0.06	t = −0.3; p = 0.80	t = −4.3; p < 0.0001	t = −2.2; p = 0.03	–	–

AD Alzheimer’s disease, MCI mild cognitive impairment